Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
AssigneeAchelois Biopharma, Inc.
InventorsMichael CHEN, Chang-Zheng CHEN
Life of this patent
Estimating the term…
Abstract
Disclosed herein, in some embodiments, is a multivalent HBV-Antivirus comprising a first fusion protein that comprises a transmembrane polypeptide and an antibody that binds to a surface protein of a hepatitis B virus (HBV) wherein the first fusion protein is expressed on a surface of the antivirus. Provided herein are antibody-based antiviruses for HBV comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a hepatitis B virus. Further provided herein are antibody-based antiviruses for HBV and methods for treating hepatitis B viral infections.
Claims185
A multivalent HBV-Antivirus comprising a first fusion protein that comprises a transmembrane polypeptide and an antibody that binds to a surface protein of a hepatitis B virus (HBV) wherein the first fusion protein is expressed on a surface of the antivirus.
A method of treating HBV in a subject in need thereof comprising:
- (a) selecting an antibody that binds to a surface protein of an HBV;
- and
- (b) expressing the antibody on a surface of a multivalent particle, wherein the multivalent particle has a binding affinity to the surface protein of the HBV that is higher than the binding affinity of a soluble version of the antibody to the surface protein of the HBV.
A method of using a multivalent HBV-Antivirus as a treatment vaccine to induce antiviral immunity against HBV or HDV in a subject infected with HBV or HDV comprising administering to the subject the HBV-Antivirus, wherein the HBV-Antivirus comprises a first fusion protein that comprises a transmembrane polypeptide and an antibody that binds to an HBV surface protein, wherein the first fusion protein is expressed on a surface of the HBV-Antivirus.
A method of using a multivalent HBV-Antivirus inactivated vaccine to induce protective immunity against HBV or HDV in a subject in need thereof comprising administering to the subject the HBV-Antivirus inactivated vaccine, wherein the HBV-Antivirus inactivated vaccine comprises an HBV and the HBV-Antivirus, wherein the HBV-Antivirus comprises a first fusion protein that comprises a transmembrane polypeptide and an antibody that binds to a HBV surface protein, wherein the first fusion protein is expressed on a surface of the HBV-Antivirus.
A composition comprising a multivalent HBV-Antivirus wherein the HBV-Antivirus comprises an enveloped particle that displays at least 10 copies of an antibody on a surface of the HBV-Antivirus, wherein the antibody binds to a surface protein of an HBV.
A composition comprising a multi-specific, multivalent HBV-Antivirus wherein the HBV-Antivirus comprises an enveloped particle that displays at least 10 copies of a multi-specific antibody on a surface of the HBV-Antivirus, wherein the multi-specific antibody binds to one or more surface proteins of an HBV.
A composition comprising a multi-specific, multivalent HBV-Antivirus wherein the HBV-Antivirus comprises an enveloped particle that displays at least 10 copies of a first antibody on a surface of the HBV-Antivirus and at least 10 copies of a second antibody on the surface of the HBV-Antivirus, wherein the first antibody binds to a surface protein of an HBV and the second antibody binds to a surface protein of the HBV, wherein the second antibody has less than 100% sequence identity to the first antibody.
A composition comprising a dual-action, immune-modulating HBV-Antivirus wherein the HBV-Antivirus comprises an enveloped particle that displays at least 10 copies of an antibody on a surface of the HBV-Antivirus and at least 10 copies of an immune modulating polypeptide on the surface of the HBV-Antivirus, wherein the antibody binds to a surface protein of an HBV.
Dependencies are inferred from the claim text.